Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bausch Health Companies Inc (TSX: BHC )

8.820 +0.190 (+2.20%)
Streaming Delayed Price Updated: 11:59 AM EDT, Jun 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Bausch Health Companies Inc

< Previous 1 2 3 Next >
Salix Partners with the Colorectal Cancer Alliance on Community Screening Program
Via ACCESSWIRE
Bausch Health to Announce First-Quarter 2023 Results on May 4
Via ACCESSWIRE
New Research: More Than Half of IBS Patients Surveyed Report Waiting More Than One Year Before Discussing IBS Symptoms With Their Healthcare Provider
Via ACCESSWIRE
Bausch Health Announces Changes to its Board of Directors
Via ACCESSWIRE
Bausch Health Announces Fourth-Quarter and Full-Year 2022 Results
Via ACCESSWIRE
Salix Announces 2023 Gastrointestinal Health Scholars Program
Via ACCESSWIRE
Bausch Health Announces Third-Quarter 2022 Results
Via ACCESSWIRE
Ortho Dermatologics to Present New Data at the 2022 Innovations in Dermatology Conference
Via ACCESSWIRE
Ortho Dermatologics Announces U.S. Launch of the Podiatry Board Review Challenge
Via ACCESSWIRE
Ortho Dermatologics To Present New Data at the 2022 Fall Clinical Dermatology Conference
Via ACCESSWIRE
Bausch Health to Announce Fourth-Quarter and Full-Year 2022 Results on Feb. 23
Via ACCESSWIRE
Bausch Health Wins DUOBRII(R) and BRYHALI(R) Patent Infringement Case
Via ACCESSWIRE
Salix Pharmaceuticals Culminates Year-Long Constipation Awareness Campaign with New Social Media and Digital Initiatives Empowering Patients to Discuss Their Symptoms with a Health Care Provider
Via ACCESSWIRE
Struggling Axsome Stock Could Bounce Back on Drug Trial Success
Axsome Pharmaceuticals may be struggling to get out of the red but the success of two very recent drug trials could quickly change all of that. 
Via MarketBeat
Exposures Product Safety
Bausch Health Announces the Unrestricting of Bausch + Lomb Under Bausch Health Debt Documents
Via ACCESSWIRE
Salix Will Present Rifaximin Data at AASLD's The Liver Meeting(R) 2022
Via ACCESSWIRE
Salix Will Present XIFAXAN(R) (Rifaximin), TRULANCE(R) (Plecanatide) and RELISTOR(R) (Methylnaltrexone Bromide) Data at The American College of Gastroenterology(R) 2022 Annual Scientific Meeting
Via ACCESSWIRE
Bausch Health to Announce Third Quarter 2022 Results on Nov. 3
Via ACCESSWIRE
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.